TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06074497
Drug: KGX101 and Envafolimab
Normalized name: cytarabine and daunorubicin
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
Study: NCT05722925
Drug: Fluciclovine PET/CT
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
Study: NCT06515990
Drug: DM005
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
Study: NCT05482893
Drug: Spevatamig (PT886)
Normalized name: PT886
DrugBank: PT886 (DB18471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
Study: NCT05482893
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort 1
Study: NCT05482893
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: Cohort 2
Study: NCT05482893
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: Cohort 2
Study: NCT05482893
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Study: NCT06519110
Drug: Neratinib tablets
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
Study: NCT06234514
Drug: intravitreal injections of 0.5mg ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
Study: NCT05503550
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered subcutaneously (SC).
Study: NCT06167317
Drug: GS-0201
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pill administered orally
Study: NCT06167317
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05512481
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year
Study: NCT05043870
Drug: Infliximab and immunosuppressives
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
Study: NCT05043870
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
Study: NCT04620759
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
Study: NCT05784246
Drug: Mirikizumab IV
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT05784246
Drug: Mirikizumab SC
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04821817
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
Study: NCT05659381
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
Study: NCT05902078
Drug: Eldecalcitol capsules
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral eldecalcitol 0.75μg daily
Study: NCT05902078
Drug: Calcitriol capsules
Normalized name: Calcitriol Capsules
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 0.5μg daily
Study: NCT05508789
Drug: Donanemab
Normalized name: Donanemab
DrugBank: Donanemab (DB16647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06498505
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Study: NCT04999969
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab
Study: NCT04999969
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy (Standard-of-Care)
Study: NCT04999969
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy (Standard-of-Care)
Study: NCT05359081
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
Study: NCT04710498
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
Study: NCT05522387
Drug: XPro1595
Normalized name: XPro1595
DrugBank: XPro1595 (DB16454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
Study: NCT05678621
Drug: trimethoprim-sulfamethoxazole (co-trimoxazole)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
Study: NCT05678621
Drug: amoxycillin/clavulanic acid and ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Study: NCT05678621
Drug: Immunoglobulins
Normalized name: IMMUNOGLOBULINS
DrugBank: Bos taurus colostrum immunoglobulins (DB17753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
Study: NCT06545331
Drug: XB010
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV administration of XB010
Study: NCT05986071
Drug: M1774
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
Study: NCT06545331
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration of Pembrolizumab
Study: NCT05160272
Drug: AP-325
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
Study: NCT05160272
Drug: Placebo matching AP-325
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
Study: NCT05986071
Drug: Fulvestrant injection
Normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
Study: NCT04747145
Drug: Concurrent Chemotherapy (Temozolomide)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
Study: NCT04747145
Drug: Adjuvant Chemotherapy (Temozolomide)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
Study: NCT06150898
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
Study: NCT06150898
Drug: Omeprazole 20mg Capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
Study: NCT05686395
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine 0.25%.
Study: NCT05215548
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
Study: NCT06249945
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
Study: NCT06484075
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug approved for improving sleep
Study: NCT04656951
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
Study: NCT06616532
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175mg/m2 via IV infusion on Day 1 Q3W
Study: NCT06616532
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25mg/m2/day via IV infusion on Days 1-5 Q3W
Study: NCT05722002
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)
Study: NCT06584071
Drug: atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: atezolizumab,1200mg, via IV infusion, Q3W
Study: NCT06584071
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab,15mg/kg, via IV infusion, Q3W
Study: NCT05704634
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by Injection under the skin every 2 weeks
Study: NCT05704634
Drug: Kevzara (Sarilumab)
Normalized name: Kevzara
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein) over about 30 minutes every 3 weeks.
Study: NCT06191978
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT06465641
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride in capsules
Study: NCT06546969
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study: NCT06546969
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study: NCT06546969
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study: NCT05638451
Drug: Sintilimab plus Bevacizumab and Temozolomide
Normalized name: Temozolomide
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
Study: NCT05010954
Drug: Lansoprazole 30mg group
Normalized name: lansoprazole 30 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
Study: NCT05800340
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 135 mg/m2, d1, 8 Q3W
Study: NCT05800340
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/m2, d1 Q3W
Study: NCT05800340
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5, d1 Q3W
Study: NCT05126472
Drug: anti-CD40 antibody 2141-V11
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
Study: NCT06584383
Drug: Best Medical Treatment
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
Study: NCT04302766
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
Study: NCT05355753
Drug: CFT8634
DrugBank: CFT-8634 (DB18443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of CFT8634
Study: NCT05126472
Drug: anti-CD40 antibody 2141-V11
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
Study: NCT04607642
Drug: BMX-001
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
Study: NCT05126472
Drug: anti-CD40 antibody 2141-V11
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
Study: NCT04607642
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
Study: NCT06053580
Drug: Valsartan 40 mg
Normalized name: valsartan 40 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 40mg twice daily for 24 weeks.
Study: NCT06256432
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Endothelin receptor antagonist
Study: NCT06256432
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin
Study: NCT06445114
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation.
Study: NCT04989413
Drug: Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: use of cannabidiol + canabigerol + thc for 12 weeks
Study: NCT06045793
Drug: TNX-1300 (Injection)
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single IV injection of TNX-1300.
Study: NCT06495723
Drug: LIS1
Normalized name: Lithium Sulfate
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
Study: NCT06269120
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
Study: NCT05319639
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
Study: NCT05319639
Drug: Levo-Leucovorin
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.